Physician profile
Guy C Oswalt
NPI 1376646505
$9,463.05
in general payments reported to CMS, 2019-2025
46 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $543 · 2021: $1,275 · 2022: $1,469 · 2023: $1,904 · 2024: $1,826 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,145.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,209.67 | 2019-2025 | Erleada, Akeega, Balversa |
| Dendreon Pharmaceuticals LLC | $1,120.10 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $682.12 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $522.69 | 2019-2024 | Lithoclast |
| Intuitive Surgical, INC. | $503.55 | 2022 | |
| Myriad Genetic Laboratories, INC. | $465.65 | 2021-2025 | Prolaris |
| Procept Biorobotics Corporation | $325.28 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Bayer Healthcare Pharmaceuticals INC. | $303.89 | 2020-2025 | |
| Pfizer INC. | $301.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $266.50 | 2021-2025 | Lynparza, Welireg, Keytruda Qlex |
| Endo Pharmaceuticals INC. | $260.61 | 2019-2023 | Xiaflex, Aveed, Edex |
| Accord Healthcare, INC. | $246.24 | 2023-2025 | |
| Astellas Pharma US INC | $241.49 | 2019-2021 | |
| Olympus America INC. | $220.60 | 2020-2024 | Itind System |
| Clarus Therapeutics INC. | $214.36 | 2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $212.22 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Medtronic, INC. | $202.25 | 2022-2023 | Interstim |
| Urogen Pharma, INC. | $187.76 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $152.82 | 2019-2024 | Yonsa |
| Janssen Scientific Affairs, LLC | $142.81 | 2024 | Erleada, Akeega |
| Myovant Sciences INC. | $134.04 | 2021-2022 | |
| Urovant Sciences INC | $123.79 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $122.80 | 2024-2025 | Adstiladrin |
| Endo USA, INC. | $120.73 | 2024-2025 | Xiaflex, Aveed |
| Axonics, INC. | $116.31 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $111.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $104.53 | 2023-2025 | |
| Blue Earth Diagnostics | $86.51 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.77 | 2022-2025 | Lynparza |
| Immunitybio, INC. | $80.00 | 2025 | |
| Progenics Pharmaceuticals, INC. | $78.35 | 2021-2024 | Pylarify |
| Coloplast Corp | $68.95 | 2019 | |
| Abbvie INC. | $65.97 | 2020-2024 | |
| Amgen INC. | $47.53 | 2020-2022 | |
| Tolmar, INC. | $47.24 | 2024-2025 | Jatenzo, Eligard |
| Rochester Medical Corporation | $44.93 | 2019-2022 | |
| Allergan, INC. | $35.97 | 2020-2021 | |
| Baxter Healthcare | $35.80 | 2019-2021 | |
| Neotract INC. | $28.89 | 2020 | |
| Ethicon US, LLC | $26.31 | 2019 | |
| Tempus Ai, INC | $24.96 | 2025 | Xt Cdx |
| Teleflex LLC | $24.37 | 2024 | Urolift |
| Innovation Technologies INC | $23.11 | 2025 | Irrisept |
| Verity Pharmaceuticals INC. | $17.67 | 2024 | Trelstar |
| Mission Pharmacal Company | $14.44 | 2022 | |
| Ambu INC. | $13.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Oswalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.